{"id":46760,"date":"2026-01-29T20:02:00","date_gmt":"2026-01-29T13:02:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=46760"},"modified":"2026-01-29T20:02:00","modified_gmt":"2026-01-29T13:02:00","slug":"micurx-announces-fda-clearance-of-ind-application-to-proceed-to-phase-2a-trial-of-mrx-5-in-patients-with-mycobacterium-abscessus-pulmonary-disease","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=46760","title":{"rendered":"MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease"},"content":{"rendered":"

FOSTER CITY, Calif.<\/span><\/span>, Jan. 29, 2026<\/span><\/span> \/PRNewswire\/ — MicuRx Pharmaceuticals, Inc. (“MicuRx”), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, recently announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MRX-5, enabling the company to initiate a Phase 2a clinical trial in patients with Mycobacterium abscessus<\/i> pulmonary disease.<\/p>\n

M. abscessus<\/i> pulmonary disease is a serious and prevalent non-tuberculous mycobacterial (NTM) infection associated with high morbidity, prolonged treatment regimens, and limited effective therapeutic options. Current treatments often require multi-drug combinations over extended periods and are frequently complicated by poor tolerability and suboptimal outcomes.<\/p>\n

MRX-5 is a novel oral antibacterial agent designed to target NTM. In preclinical studies, MRX-5 demonstrated potent activity against clinical isolates of M. abscessus<\/i>, including strains resistant to existing standard-of-care therapies. The compound has also shown favorable pharmacokinetic and safety profiles in nonclinical and clinical studies.<\/p>\n

“The FDA’s clearance of our IND for MRX-5 represents an important milestone for MicuRx and for patients suffering from M. abscessus<\/i> pulmonary disease,” said President of MicuRx Jerry (Zhiyue) Li “This approval allows us to advance MRX-5 into a Phase 2a clinical trial,\u00a0 which aim to assess its safety, and efficacy in patients with M. abscessus<\/i> pulmonary disease.”<\/p>\n

The Phase 2a trial is a multicenter study in the United States<\/span> designed to evaluate MRX-5 in adults with confirmed M. abscessus<\/i> pulmonary disease. The trial is expected to generate important clinical data to inform subsequent development\u00a0 milestones.<\/p>\n

This IND clearance further expands MicuRx’s clinical pipeline of anti-infective drugs, reinforcing the company’s commitment to addressing global challenges posed by antimicrobial resistance and difficult-to-treat bacterial infections.<\/p>\n

About MRX-5<\/b><\/p>\n

MRX-5 is a next-generation antibacterial agent being developed by MicuRx for the treatment of non-tuberculous mycobacterial infections, including M. abscessus<\/i>. The compound is designed for oral administration and aims to provide a more effective and tolerable treatment option.<\/p>\n

FDA granted orphan drug designation to MRX-5 for the treatment of NTM infections in 2024.<\/p>\n

About MicuRx<\/b><\/p>\n

MicuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat serious and drug-resistant bacterial infections. Leveraging deep expertise in medicinal chemistry and anti-infective drug development, MicuRx aims to deliver differentiated therapies to address significant unmet medical needs worldwide.<\/p>\n

\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

FOSTER CITY, Calif.<\/span><\/span>, Jan. 29, 2026<\/span><\/span> \/PRNewswire\/ — MicuRx Pharmaceuticals, Inc. (“MicuRx”), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, recently announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MRX-5, enabling the company to initiate a Phase 2a clinical trial in patients with Mycobacterium abscessus<\/i> pulmonary disease.<\/p>\n

M. abscessus<\/i> pulmonary disease is a serious and prevalent non-tuberculous mycobacterial (NTM) infection associated with high morbidity, prolonged treatment regimens, and limited effective therapeutic options. Current treatments often require multi-drug combinations over extended periods and are frequently complicated by poor tolerability and suboptimal outcomes.<\/p>\n

MRX-5 is a novel oral antibacterial agent designed to target NTM. In preclinical studies, MRX-5 demonstrated potent activity against clinical isolates of M. abscessus<\/i>, including strains resistant to existing standard-of-care therapies. The compound has also shown favorable pharmacokinetic and safety profiles in nonclinical and clinical studies.<\/p>\n

“The FDA’s clearance of our IND for MRX-5 represents an important milestone for MicuRx and for patients suffering from M. abscessus<\/i> pulmonary disease,” said President of MicuRx Jerry (Zhiyue) Li “This approval allows us to advance MRX-5 into a Phase 2a clinical trial,\u00a0 which aim to assess its safety, and efficacy in patients with M. abscessus<\/i> pulmonary disease.”<\/p>\n

The Phase 2a trial is a multicenter study in the United States<\/span> designed to evaluate MRX-5 in adults with confirmed M. abscessus<\/i> pulmonary disease. The trial is expected to generate important clinical data to inform subsequent development\u00a0 milestones.<\/p>\n

This IND clearance further expands MicuRx’s clinical pipeline of anti-infective drugs, reinforcing the company’s commitment to addressing global challenges posed by antimicrobial resistance and difficult-to-treat bacterial infections.<\/p>\n

About MRX-5<\/b><\/p>\n

MRX-5 is a next-generation antibacterial agent being developed by MicuRx for the treatment of non-tuberculous mycobacterial infections, including M. abscessus<\/i>. The compound is designed for oral administration and aims to provide a more effective and tolerable treatment option.<\/p>\n

FDA granted orphan drug designation to MRX-5 for the treatment of NTM infections in 2024.<\/p>\n

About MicuRx<\/b><\/p>\n

MicuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat serious and drug-resistant bacterial infections. Leveraging deep expertise in medicinal chemistry and anti-infective drug development, MicuRx aims to deliver differentiated therapies to address significant unmet medical needs worldwide.<\/p>\n

\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1],"tags":[],"class_list":["post-46760","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/46760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46760"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/46760\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}